T1	Quantitative_concept 4 9	first
T2	Disease_disorder 18 60	a 76-year-old man with atrial fibrillation
T3	Lab 32 35	man
T4	Disease_disorder 41 60	atrial fibrillation
T5	Anatomical_structure 41 47	atrial
T6	Disease_disorder 48 60	fibrillation
T7	Disease_disorder 62 85	previous embolic stroke
T8	Disease_disorder 71 85	embolic stroke
T9	Disease_disorder 79 85	stroke
T10	Disease_disorder 87 104	diabetes mellitus
T11	Disease_disorder 87 95	diabetes
T12	Disease_disorder 106 118	hypertension
T13	Disease_disorder 124 150	nonischemic cardiomyopathy
T14	Disease_disorder 136 150	cardiomyopathy
T15	Procedure 152 159	His ECG
T16	Diagnostic_procedure 156 159	ECG
T17	Disease_disorder 166 185	atrial fibrillation
T18	Disease_disorder 166 254	atrial fibrillation and left bundle-branch block with a QRS duration of 180 milliseconds
T19	Anatomical_structure 166 172	atrial
T20	Disease_disorder 173 185	fibrillation
T21	Disease_disorder 190 214	left bundle-branch block
T22	Anatomical_structure 190 208	left bundle-branch
T23	Disease_disorder 195 214	bundle-branch block
T24	Disease_disorder 209 214	block
T25	Lab 222 234	QRS duration
T26	Medication 226 234	duration
T27	Sign_symptom 260 298	his left ventricular ejection fraction
T28	Sign_symptom 264 298	left ventricular ejection fraction
T29	Sign_symptom 281 289	ejection
T30	Procedure 316 368	long-term warfarin therapy with a CHADS 2 score of 5
T31	Lab 326 334	warfarin
T32	Procedure 335 342	therapy
T33	Lab 350 355	CHADS
T34	Quantitative_concept 358 363	score
T35	Sign_symptom 373 413	an estimated annual risk of ATE of 12.5%
T36	Quantitative_concept 376 397	estimated annual risk
T37	Disease_disorder 401 404	ATE
T38	Quantitative_concept 415 416	2
T39	Procedure 439 451	implantation
T40	Procedure 439 496	implantation of a cardiac resynchronization defibrillator
T41	Anatomical_structure 457 464	cardiac
T42	Medication 509 521	his warfarin
T43	Lab 513 521	warfarin
T44	Activity 525 532	managed
T45	Procedure 540 558	the device surgery
T46	Procedure 551 558	surgery
T47	Sign_symptom 584 617	concerns about periprocedural ATE
T48	Sign_symptom 614 617	ATE
T49	Qualitative_concept 630 641	moderate-to
T50	Medication 630 682	moderate-to high-risk patients with heparin bridging
T51	Qualitative_concept 642 651	high-risk
T52	Medication 666 673	heparin
T53	Quantitative_concept 737 738	3
T54	Procedure 748 811	a number of downsides to heparin bridging around device surgery
T55	Quantitative_concept 750 756	number
T56	Lab 773 780	heparin
T57	Procedure 804 811	surgery
T58	Quantitative_concept 827 832	First
T59	Disease_disorder 843 910	a substantial risk of clinically significant device pocket hematoma
T60	Qualitative_concept 876 887	significant
T61	Disease_disorder 902 910	hematoma
T62	Qualitative_concept 911 918	related
T63	Medication 922 929	heparin
T64	Medication 922 938	heparin bridging
T65	Disease_disorder 940 974	The risk of hematoma with bridging
T66	Disease_disorder 952 960	hematoma
T67	Quantitative_concept 999 1002	4,5
T68	Disease_disorder 1016 1039	device pocket hematomas
T69	Disease_disorder 1030 1039	hematomas
T70	Activity 1066 1075	cessation
T71	Lab 1079 1094	anticoagulation
T72	Disease_disorder 1122 1126	ATEs
T73	Medication 1165 1207	the duration and cost of hospitalization 7
T74	Medication 1169 1177	duration
T75	Quantitative_concept 1182 1186	cost
T76	Procedure 1224 1235	reoperation
T77	Disease_disorder 1271 1312	an association between hematoma formation
T78	Qualitative_concept 1274 1285	association
T79	Disease_disorder 1294 1302	hematoma
T80	Disease_disorder 1317 1351	subsequent device system infection
T81	Disease_disorder 1342 1351	infection
T82	Procedure 1357 1419	example in the Implantable Cardiac Pulse Generator Replacement
T83	Anatomical_structure 1384 1391	Cardiac
T84	Procedure 1408 1419	Replacement
T85	Disease_disorder 1440 1466	8 patients with infections
T86	Disease_disorder 1456 1466	infections
T87	Disease_disorder 1472 1479	20-fold
T88	Qualitative_concept 1485 1491	likely
T89	Lab 1492 1494	to
T90	Disease_disorder 1504 1527	postoperative hematomas
T91	Disease_disorder 1518 1527	hematomas
T92	Disease_disorder 1529 1553	Device system infections
T93	Disease_disorder 1543 1553	infections
T94	Qualitative_concept 1558 1565	serious
T95	Qualitative_concept 1592 1599	usually
T96	Procedure 1608 1631	complete system removal
T97	Procedure 1624 1631	removal
T98	Qualitative_concept 1643 1654	significant
T99	Qualitative_concept 1655 1665	associated
T100	Quantitative_concept 1666 1675	morbidity
T101	Quantitative_concept 1677 1686	mortality
T102	Quantitative_concept 1692 1714	cost to the healthcare
T103	Quantitative_concept 1692 1696	cost
T104	Medication 1723 1763	The second problem with heparin bridging
T105	Lab 1727 1741	second problem
T106	Lab 1734 1741	problem
T107	Lab 1747 1754	heparin
T108	Sign_symptom 1781 1812	a phase of normal coagulability
T109	Sign_symptom 1792 1798	normal
T110	Disease_disorder 1822 1845	even hypercoagulability
T111	Disease_disorder 1827 1845	hypercoagulability
T112	Qualitative_concept 1846 1853	related
T113	Procedure 1857 1891	the prothrombotic state of surgery
T114	Procedure 1884 1891	surgery
T115	Qualitative_concept 1894 1909	with associated
T116	Disease_disorder 1918 1922	ATEs
T117	Lab 1927 1935	response
T118	Sign_symptom 1927 1951	response to these issues
T119	Sign_symptom 1945 1951	issues
T120	Qualitative_concept 1966 1973	started
T121	Diagnostic_procedure 1985 1994	pacemaker
T122	Procedure 1999 2069	defibrillator surgery without interruption of warfarin anticoagulation
T123	Procedure 2013 2020	surgery
T124	Lab 2045 2053	warfarin
T125	Lab 2054 2069	anticoagulation
T126	Disease_disorder 2071 2075	9,10
T127	Lab 2076 2085	Physician
T128	Disease_disorder 2094 2103	indicated
T129	Qualitative_concept 2104 2112	clinical
T130	Lab 2113 2122	equipoise
T131	Qualitative_concept 2141 2145	need
T132	Quantitative_concept 2179 2184	large
T133	Medication 2220 2228	Warfarin
T134	Sign_symptom 2220 2269	Warfarin for Device Surgery Randomized Controlled
T135	Procedure 2240 2247	Surgery
T136	Disease_disorder 2277 2283	BRUISE
T137	Qualitative_concept 2284 2291	CONTROL
T138	Activity 2298 2307	published
T139	Lab 2349 2351	n=
T140	Disease_disorder 2379 2382	ATE
T141	Quantitative_concept 2388 2390	5%
T142	Lab 2427 2435	warfarin
T143	Lab 2439 2446	heparin
T144	Qualitative_concept 2461 2468	primary
T145	Qualitative_concept 2492 2503	significant
T146	Disease_disorder 2492 2512	significant hematoma
T147	Disease_disorder 2504 2512	hematoma
T148	Lab 2593 2608	anticoagulation
T149	Procedure 2623 2634	reoperation
T150	Qualitative_concept 2649 2654	Major
T151	Procedure 2655 2663	surgical
T152	Disease_disorder 2683 2696	complications
T153	Qualitative_concept 2702 2706	rare
T154	Qualitative_concept 2729 2738	different
T155	Lab 2747 2751	arms
T156	Disease_disorder 2767 2768	1
T157	Disease_disorder 2767 2797	1 episode of cardiac tamponade
T158	Procedure 2780 2797	cardiac tamponade
T159	Anatomical_structure 2780 2787	cardiac
T160	Procedure 2788 2797	tamponade
T161	Disease_disorder 2802 2853	1 myocardial infarction in the heparin-bridging arm
T162	Disease_disorder 2804 2849	myocardial infarction in the heparin-bridging
T163	Disease_disorder 2804 2825	myocardial infarction
T164	Disease_disorder 2815 2825	infarction
T165	Lab 2833 2849	heparin-bridging
T166	Lab 2850 2853	arm
T167	Disease_disorder 2859 2867	1 stroke
T168	Disease_disorder 2861 2867	stroke
T169	Disease_disorder 2872 2929	1 transient ischemic attack in the continued-warfarin arm
T170	Disease_disorder 2874 2899	transient ischemic attack
T171	Disease_disorder 2884 2929	ischemic attack in the continued-warfarin arm
T172	Sign_symptom 2893 2899	attack
T173	Lab 2907 2925	continued-warfarin
T174	Qualitative_concept 2947 2954	similar
T175	Procedure 2958 3011	those in a meta-analysis of the observational studies
T176	Disease_disorder 3013 3015	10
T177	Medication 3026 3049	the basis of these data
T178	Medication 3030 3035	basis
T179	Lab 3055 3062	patient
T180	Procedure 3075 3122	device surgery without interruption of warfarin
T181	Procedure 3082 3089	surgery
T182	Lab 3114 3122	warfarin
T183	Activity 3124 3127	see
T184	Qualitative_concept 3147 3151	full
T185	Diagnostic_procedure 3152 3161	algorithm
T186	Lab 3168 3175	patient
T187	Qualitative_concept 3189 3196	similar
T188	Lab 3255 3265	dabigatran
T189	Procedure 3255 3272	dabigatran 150 mg
T190	Procedure 3270 3272	mg
T191	Procedure 3292 3312	creatinine clearance
T192	Medication 3292 3302	creatinine
T193	Quantitative_concept 3338 3339	3
T194	Qualitative_concept 3340 3343	new
T195	Qualitative_concept 3357 3365	approved
T196	Disease_disorder 3370 3402	use for the prevention of stroke
T197	Procedure 3382 3392	prevention
T198	Disease_disorder 3396 3402	stroke
T199	Disease_disorder 3407 3461	systemic embolism in patients with atrial fibrillation
T200	Disease_disorder 3416 3424	embolism
T201	Disease_disorder 3442 3461	atrial fibrillation
T202	Anatomical_structure 3442 3448	atrial
T203	Disease_disorder 3449 3461	fibrillation
T204	Lab 3485 3495	experience
T205	Lab 3501 3511	dabigatran
T206	Lab 3516 3527	rivaroxaban
T207	Activity 3538 3547	published
T208	Quantitative_concept 3557 3563	points
T209	Diagnostic_procedure 3577 3584	studies
T210	Disease_disorder 3611 3612	1
T211	Lab 3642 3660	procedures/surgery
T212	Quantitative_concept 3665 3671	common
T213	Disease_disorder 3681 3684	10%
T214	Quantitative_concept 3716 3717	2
T215	Disease_disorder 3725 3728	10%
T216	Diagnostic_procedure 3768 3777	pacemaker
T217	Procedure 3781 3802	defibrillator surgery
T218	Procedure 3795 3802	surgery
T219	Quantitative_concept 3804 3805	3
T220	Qualitative_concept 3812 3817	brief
T221	Qualitative_concept 3907 3922	associated with
T222	Lab 3975 3984	patient's
T223	Lab 3985 3995	dabigatran
T224	Lab 4006 4010	held
T225	Activity 4038 4041	see
T226	Procedure 4042 4115	the Table for suggested period of NOAC interruption before device surgery
T227	Lab 4076 4080	NOAC
T228	Procedure 4108 4115	surgery
T229	Lab 4136 4138	to
T230	Qualitative_concept 4153 4160	restart
T231	Lab 4165 4169	drug
T232	Qualitative_concept 4199 4204	NOACs
T233	Qualitative_concept 4210 4219	restarted
T234	Lab 4227 4238	physician's
T235	Lab 4255 4265	hemostasis
T236	Qualitative_concept 4270 4282	satisfactory
T237	Lab 4336 4340	NOAC
T238	Qualitative_concept 4351 4356	rapid
T239	Qualitative_concept 4383 4390	effects
T240	Qualitative_concept 4391 4398	similar
T241	Disease_disorder 4444 4450	result
T242	Disease_disorder 4444 4486	result in significant numbers of hematomas
T243	Qualitative_concept 4454 4465	significant
T244	Quantitative_concept 4466 4473	numbers
T245	Disease_disorder 4477 4486	hematomas
T246	Lab 4503 4510	patient
T247	Sign_symptom 4517 4543	an annual risk of ATE > 5%
T248	Disease_disorder 4535 4538	ATE
T249	Quantitative_concept 4541 4543	5%
T250	Procedure 4569 4620	the first dose of dabigatran 24 hours after surgery
T251	Quantitative_concept 4573 4578	first
T252	Quantitative_concept 4579 4583	dose
T253	Lab 4587 4597	dabigatran
T254	Procedure 4613 4620	surgery
T255	Disease_disorder 4641 4651	lower risk
T256	Disease_disorder 4655 4658	ATE
T257	Quantitative_concept 4661 4663	5%
T258	Lab 4691 4693	to
T259	Procedure 4704 4726	48 hours after surgery
T260	Procedure 4719 4726	surgery
T261	Lab 4751 4753	to
T262	Activity 4754 4760	refine
T263	Procedure 4761 4826	all of these recommendations about NOAC management around surgery
T264	Lab 4796 4800	NOAC
T265	Sign_symptom 4801 4811	management
T266	Procedure 4819 4826	surgery
